Cancer Related Fatigue (CRF) stellt das häufigste Krebs- und Krebstherapie-assoziierte Symptom mit großem Einfluss auf die Lebensqualität dar. Hohen Prävalenzzahlen unter adjuvanter Therapie (70–92%) und in palliativen Erkrankungsstadien sowie eine gehäufte Persistenz auch in krankheitsfreien Intervallen (20–36% nach 1–8 Jahren) stehen immer noch unzureichende Therapieangebote in der alltäglichen medizinischen Versorgung gegenüber. Aufgrund des gehäuften chronischen Verlaufs und der Komplexizität der Beschwerden, wie auch der unzureichenden Therapie von CRF-Patienten, besteht ein großer Bedarf an multimodal konzipierten Rehabilitationsmaßnahmen, welche allerdings ihren Stellenwert erst in klinischen Studien belegen müssen.
Abstract
Cancer Related Fatigue (CRF) is the symptom most commonly associated with cancer and cancer therapy that has a significant impact on quality of life. Prevalence is high during adjuvant therapy (70–92%) as well as palliative stages of the disease, and it frequently persists in the disease free interval too (20–36% after 1–8 years). Treatment options routinely offered in medical care are thus fare largely insufficient. There is ample demand for a concept of multimodal rehabilitating measures, because fatigue often becomes chronic, complaints are frequently complex and there are only limited therapeutic options for CRF patients. Hence, these measures have still to prove their significance in clinical studies.
Schlüsselwörter
Cancer Related Fatigue (CRF) - Insomnie - multimodale Therapiekonzepte - Ruhe/Aktivitätsrhythmus
Key words
Cancer Related Fatigue (CRF) - insomnia - multimodal therapy concepts - rest/activity-rhythm
1 Die Autoren danken Dagmar Brauer für die grafische Darstellung der Abbildungen und die Mitarbeit an der Erstellung des Manuskriptes. Diese Arbeit wurde vom Humanus-Institut, Institut für Altersforschung und der Software AG-Stiftung gefördert.
Literatur
1
NCI
.
Fatigue (PDQ).
U. S. National Institutes of Health.
Accessed 06/24/2009, 2009
6
Dimeo F, Schmittel A, Fietz T. et al .
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment.
Ann Oncol.
2004;
15
1237-1242
7
Stone P, Richardson A, Ream E. et al .
Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.
Ann Oncol.
2000;
11
971-975
9
Bower JE, Ganz PA, Desmond KA. et al .
Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life.
J Clin Oncol.
2000;
18
743-753
10
Ahn SH, Park BW, Noh DY. et al .
Health-related quality of life in disease-free survivors of breast cancer with the general population.
Ann Oncol.
2007;
18
173-182
12
Glaus A, Muller S.
Measuring fatigue of cancer patients in the German-speaking region: development of the Fatigue Assessment Questionnaire.
Pflege.
2001;
14
161-170
14
Radbruch L, Sabatowski R, Elsner F. et al .
Validation of the German version of the brief fatigue inventory.
J Pain Symptom Manage.
2003;
25
449-458
15
McElroy JA, Newcomb PA, Titus-Ernstoff L. et al .
Duration of sleep and breast cancer risk in a large population-based case-control study.
J Sleep Res.
2006;
15
241-249
18
Roscoe JA, Morrow GR, Hickok JT. et al .
Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment.
Support Care Cancer.
2002;
10
329-336
19
Mormont MC, Waterhouse J, Bleuzen P. et al .
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Clin Cancer Res.
2000;
6
3038-3045
20
Innominato PF, Focan C, Gorlia T. et al .
Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.
Cancer Res.
2009;
69
4700-4707
24
Servaes P, Prins J, Verhagen S. et al .
Fatigue after breast cancer and in chronic fatigue syndrome: Similarities and differences.
J Psychosom Res.
2002;
52
453-459
26
Matsuda T, Takayama T, Tashiro M. et al .
Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients – evaluation of appropriate research design and methodology to measure symptoms.
Breast Cancer.
2005;
12
279-287
27
Fan HG, Houede-Tchen N, Yi QL. et al .
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
J Clin Oncol.
2005;
23
8025-8032
29
Groenvold M, Petersen MA, Idler E. et al .
Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients.
Breast Cancer Res Treat.
2007;
105
209-219
32 Hamann T. Das subjektive Rehabilitationsbedürfnis von Frauen mit Brustkrebs [Med.Inaug.Diss]. Hannover: Institut für Physikalische Medizin, Medizinische Hochschule Hannover; 2007
33 Hübner J. Lebensqualität und Symptome von Patientinnen mit Mammakarzinom – Abschätzung und Entwicklung eines Rehabilitationsbedarfsscors. Hannover: Klinik für Physikalische Medizin, Medizinische Hochschule Hannover; 2009
35 Aaronson N.
The European Organisation for Research and Treatment of Cancer (EORTC)
.Modular Approach to Quality of Life.. Assessment in Oncology. An Up-date. New York Raven Press; 1994
37
Deck R, Kohlmann T, Raspe H.
Erwartungen und Motivation bei Patienten in der medizinischen Rehabilitation.
Z f Gesundheitspsychologie.
1998;
6
101-108
39 Herrmann C, Buss U. HADS-D, Hospital Anxiety and Depression Scale- Deutsche Version.. Testdokumentation und Handanweisung. Bern, Göttingen, Toronto, Seattle: Verlag Hans Huber; 1995
40
Schwarz R, Hinz A.
Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population.
Eur J Cancer.
2001;
37
1345-1351
43
Straus DJ, Testa MA, Sarokhan BJ. et al .
Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Cancer.
2006;
107
1909-1917
44
Bohlius J, Schmidlin K, Brillant C. et al .
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials.
Lancet.
2009;
373
1532-1542
45
Dimeo FC, Stieglitz RD, Novelli-Fischer U. et al .
Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy.
Cancer.
1999;
85
2273-2277
46
Spiegel D, Bloom JR, Kraemer HC. et al .
Effect of psychosocial treatment on survival of patients with metastatic breast cancer.
Lancet.
1989;
2
888-891
47
Carlson LE, Ursuliak Z, Goodey E. et al .
The effects of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up.
Support Care Cancer.
2001;
9
112-123
48
Bruera E, Valero V, Driver L. et al .
Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial.
J Clin Oncol.
2006;
24
2073-2078
49
Piao BK, Wang YX, Xie GR. et al .
Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
Anticancer Res.
2004;
24
303-309
50
Semiglazov VF, Stepula VV, Dudov A. et al .
Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: A randomised, placebo-controlled, double-blind, multicentre clinical trial.
Anticancer Res.
2006;
26
1519-1529
1 Die Autoren danken Dagmar Brauer für die grafische Darstellung der Abbildungen und die Mitarbeit an der Erstellung des Manuskriptes. Diese Arbeit wurde vom Humanus-Institut, Institut für Altersforschung und der Software AG-Stiftung gefördert.
